Piper Sandler analyst Matt O’Brien lowered the firm’s price target on OrthoPediatrics (KIDS) to $22 from $30 and keeps an Overweight rating on the shares after the company preannounced Q3 revenue results that missed the firm and Street’s estimates by 6%/4%. The company also lowered full-year revenue and long-term growth rate expectations. While the update is frustrating, Piper believes management is “kitchen-sinking” its revenue outlook to get to a place it can meet and likely exceed in the future in order to start getting credit from a stock perspective. Consequently, the firm would take advantage of likely weakness in the stock.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics: Strong Growth Prospects and Acquisition Potential Justify Buy Rating
- Closing Bell Movers: Levi Strauss down 8% after results
- OrthoPediatrics reports preliminary Q3 revenue $61.2M, consensus $63.63M
- OrthoPediatrics cuts FY25 revenue view to $233.5M-$234.5M from $237M-$242M
- OrthoPediatrics preliminary Q3 revenue $61.2M, consensus $63.63M